Impact of IL-37 on Oxidant-Antioxidant Status in Chronic Liver Failure

Maha.D Azeez

Maha.D Azeez Department of Pharmaceutical Chemistry, College of Pharmacy, University of Thi-Qar, Thi-Qar, 64001, Iraq

Keywords: Chronic liver failure, IL-37, Oxidant, Oxidative Stress

Abstract

Chronic liver failure, characterized by the permanent and gradual loss of liver function over time, is influenced by oxidative stress and inflammation. This study aimed to evaluate the association between interleukin-37 (IL-37) and oxidant-antioxidant status in patients with chronic liver failure, given that IL-37 is activated by reactive oxygen species (ROS). Conducted at Al-AL-Hussein Teaching Hospital in Thi-Qar governorate from August 20, 2023, to February 25, 2024, the study involved 40 patients and 40 controls aged 20 to 60. Blood samples were collected and analyzed using ELISA and other biochemical methods. Results indicated significantly higher levels of IL-37, malondialdehyde (MDA), and ceruloplasmin (Cp) in patients compared to controls (P < 0.05), while levels of albumin, glutathione (GSH), and superoxide dismutase (SOD) were significantly lower. A positive correlation was found between IL-37, MDA, and Cp, whereas a negative correlation was observed between IL-37 and albumin, GSH, and SOD. These findings suggest that IL-37 may play a role in the oxidative stress observed in chronic liver failure, highlighting potential targets for therapeutic intervention.

References

A. Allameh, R. Niayesh-Mehr, A. Aliarab, G. Sebastiani, and K. Pantopoulos, "Oxidative Stress in Liver Pathophysiology and Disease," Antioxidants, vol. 12, pp. 1653, 2023.

G. Baffy, E. M. Brunt, and S. H. Caldwell, "Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace," J. Hepatol., vol. 56, pp. 1384–1391, 2012.

A. Bose Mazumdar Ghosh, A. Banerjee, and S. Chattopadhyay, "An insight into the potent medicinal plant Phyllanthus amarus Schum. and Thonn," Nucleus (Calcutta), vol. 65, pp. 437–472, 2022.

M. L. Contreras-Zentella, D. Villalobos-García, and R. Hernández-Muñoz, "Ethanol metabolism in the liver, the induction of oxidant stress, and the antioxidant defense system," Antioxidants (Basel), vol. 11, pp. 1258, 2022.

N. Chhikara, A. Kaur, S. Mann, M. K. Garg, S. A. Sofi, and A. Panghal, "Bioactive compounds, associated health benefits and safety considerations of Moringa oleifera L.: an updated review," Nutrition & Food Science, vol. 51, pp. 255–277, 2021.

H. M. Chen and M. Fujita, "IL-37: a new player in immune tolerance," Cytokine, vol. 72, pp. 113–114, 2015.

N. V. Emanuele, T. F. Swade, and M. A. Emanuele, "Consequences of alcohol use in diabetics," Alcohol Health Res World, vol. 22, pp. 211–219, 1998.

P. Farzanegi, A. Dana, Z. Ebrahimpoor, M. Asadi, and M. A. Azarbayjani, "Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation," Eur J Sport Sci, vol. 19, pp. 994–1003, 2019.

F. Yang, Y. Zhang, and H. Liang, "Interactive Association of Drugs Binding to Human Serum Albumin," Int. J. Mol. Sci., vol. 15, pp. 3580–3595, 2014.

J. M. Gutteridge, "Inhibition of the Fenton Reaction by the Protein Ceruloplasmin and Other Copper Complexes. Assessment of Feroxidase and Radical Scavenging Activities," Chem. Biol. Interact., vol. 56, pp. 113–120, 2005.

B. Halliwell, "Antioxidant defence mechanisms: From the beginning to the end (of the beginning)," Free Radic. Res., vol. 31, pp. 261–272, 1999.

H. Jaeschke and A. Ramachandran, "Reactive oxygen species in the normal and acutely injured liver," J. Hepatol., vol. 55, pp. 227–228, 2011.

B. Jiang, Y. Zhou, Y. Liu, S. He, B. Liao, T. Peng, L. Yao, and L. Qi, "Research Progress on the Role and Mechanism of IL-37 in Liver Diseases," Semin Liver Dis., vol. 43, no. 3, pp. 336–350, Aug. 2023.

C. Menden, J. Boian, L. Murthy, and H. Petering, "Plasma Antioxidant," Anal Lett., vol. 10, pp. 197, 1977.

R. D. Muslih, M. A. Al-Nimer, and O. M. Al-Zamely, "The Level of Malondialdehyde after Activation with H2O2 and CuSO4) and Inhibited by Desferoxamine and Molsidomine in the Serum of Patients with Acute Myocardial Infection," Nat. J. Chem., vol. 5, pp. 148–149, 2002.

M. Taverna, A. L. Marie, J. P. Mira, and B. Guidet, "Specific Antioxidant Properties of Human Serum Albumin," Ann. Intensive Care, vol. 3, no. 4, 2013.

N. Rafiq, C. Bai, Y. Fang, M. Srishord, A. McCullough, T. Gramlich, and Z. M. Younossi, "Long-term follow-up of patients with nonalcoholic fatty liver," Clin Gastroenterol Hepatol, vol. 7, pp. 234–238, 2009.

R. Rouf, P. Ghosh, M. R. Uzzaman, D. K. Sarker, F. T. Zahura, S. J. Uddin, and I. Muhammad, "Hepatoprotective plants from Bangladesh: a biophytochemical review and future prospect," Evid Based Complement Alternat Med, vol. 2021, pp. 1633231, 2021.

S. A. Sayer, A. F. Yousif, and R. N. Aljabery, "A Review on Some Biochemical markers in Metabolic-Associated Fatty Liver Disease," UTJSci, vol. 10, no. 1, 2023.

S. A. Sayer, M. H. Alsalih Raid, and T. Al- Khafaji Adnan, "Biochemical Comparative Study For Study For Serum Oxidant-Antioxidants Status in Elderly Patients With Atrial Fibrillation," World J. Pharm. Pharm. Sci., vol. 6, no. 3, 2017.

P. Sharma, M. Nandave, D. Nandave, S. Yadav, C. Vargas-De-La-Cruz, S. Singh, R. Tandon, S. Ramniwas, and T. Behl, "Reactive oxygen species (ROS)-mediated oxidative stress in chronic liver diseases and its mitigation by medicinal plants," Am J Transl Res, vol. 15, no. 11, pp. 6321–6341, Nov. 2023.

A. Sharma and S. Nagalli, "Chronic Liver Disease," StatPear ls Publishing, 2024.

M. Shao, Y. Wang, H. Dong, L. Wang, X. Zhang, X. Han, X. Sang, Y. Bao, M. Peng, G. Cao, "From liver fibrosis to hepatocarcinogenesis: role of excessive liver H2O2 and targeting nanotherapeutics," Bioact Mater, vol. 23, pp. 187–205, 2022.

H. Sies, C. Berndt, and D. P. Jones, "Oxidative stress," Annu. Rev. Biochem., vol. 86, pp. 715–748, 2017.

F. S. Wang, J. G. Fan, Z. Zhang, B. Gao, and H. Y. Wang, "The global burden of liver disease: the major impact of China," Hepatology, vol. 60, no. 6, pp. 2099–2108, 2014.

B. Wu, K. Meng, Q. Ji, M. Cheng, K. Yu, X. Zhao, T. H., Y. Liu, Y. Zhou, C. Chang et al., "Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice," Clin Exp Immunol, vol. 176, pp. 438–451, 2014.

D. Webster, "Role of Oxidative Stress in Diabetic Complication," Clin. Chem. J., vol. 53, pp. 109, 1974.

W. D. Xu, Y. Zhao, and Y. Liu, "Insights into IL-37, the role in autoimmune diseases," Autoimmun Rev, vol. 12, pp. 1170–1175, 2015.

J. D. Yang, P. Hainaut, G. J. Gores, A. Amadou, A. Plymoth, and L. R. Roberts, "A global view of hepatocellular carcinoma: trends, risk, prevention and management," Nat Rev Gastroenterol Hepatol, vol. 16, no. 10, pp. 589–604, 2019.

X. Yan, B. Xie, G. Wu, J. Hu, D. Wang, X. Cai, and J. Li, "Interleukin-37: The Effect of Anti-Inflammatory Response in Human Coronary Artery Endothelial Cells," Mediators Inflamm., vol. 2019, pp. 2650590, Jan. 8, 2019.

Z. M. Younossi, T. Gramlich, C. A. Matteoni, N. Boparai, and A. J. McCullough, "Nonalcoholic fatty liver disease in patients with type 2 diabetes," Clin Gastroenterol Hepatol, vol. 2, pp. 262–265, 2004.

A. K. Zaid and S. A. Sayer, "Association Abnormal Levels of Serum Interleukin-33, Interleukin-23 With Oxidant-Antioxidants Status in Patients With Acute Liver Failure," J. Sci., vol. 9, pp. 94–99, 2022.